**INTRODUCTION**

Dietary sugars induce an increase in hepatic de novo lipogenesis (DNL), which left unchecked promotes liver inflammation, ultimately leading to the development of fibrosis and nonalcoholic steatohepatitis (NASH). Pharmacologic inhibition of fatty acid synthase (FASN), a key enzyme in the DNL pathway, treats steatosis, inflammation and fibrosis in high-fat, high-fructose fed (HFFD) murine models (see Poster 1994 for a full description of the murine data).

One compelling mechanism for NASH treatment is inhibition of the driver of this progressive disease, specifically reduction of hepatic lipogenesis mediated by FASN. 3-V Biosciences has developed the highly selective FASN inhibitor, TVB-2640, and evaluated it in early phase clinical studies.

**AIM**

The primary objective of this human pharmacology study was to determine the extent that TVB-2640 could inhibit DNL in subjects with BMI >26 and characteristics of metabolic syndrome.

**MATERIAL & METHODS**

For murine studies, animals were fed high fat, high fructose diet (HFFD) for 44 weeks and the presence of liver fibrosis was confirmed by biopsy. The HFFD diet was continued for an additional 8 weeks in addition to daily oral dosing with the FASN inhibitor, TVB-3664, or vehicle without drug (Fig. 1). For a full description of the methods used for the murine model, please see Poster 1994.

The PK of TVB-2640 was evaluated in 20 healthy volunteers; each subject received one 50mg capsule of drug on an empty stomach and blood collected at intervals up to 48 hours (Fig. 2). The impact of TVB-2640 on DNL was evaluated in healthy males with a BMI above 26 and characteristics of metabolic syndrome (ie elevated triglycerides and fasting blood glucose levels) (Table 1). DNL was measured once prior to dosing and once after 10 days of once-daily, oral TVB-2640 (Fig. 3). To measure DNL, the subject received an IV infusion of 13C-acetate overnight followed by drinking a fructose/glucose solution the next morning. Blood samples were collected and labeled palmitate was measured in VLDL-TG to evaluate the proportion of fatty acids derived from DNL. TVB-2640 had a significant impact on DNL at all doses tested (Figs. 4 and 5) and was generally well-tolerated in these subjects (Table 2).

**RESULTS**

**Figure 1.** Treatment of mice with diet-induced NASH with the FASN inhibitor, TVB-3664*:

TVB-3646 reduces liver fat in mice with existing steatohepatitis and fibrosis

**Table 1.** Demographics of subjects in the clinical pharmacology study (males only)

<table>
<thead>
<tr>
<th>N</th>
<th>Dose</th>
<th>%Change</th>
<th>%Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>50mg</td>
<td>Mean(range)</td>
<td>Mean(range)</td>
</tr>
<tr>
<td>20</td>
<td>150mg</td>
<td>Mean(range)</td>
<td></td>
</tr>
</tbody>
</table>

**Figure 2.** A single oral dose of TVB-2640 (50mg) is well absorbed and has a half-life of >9 hours

**Human PK TVB-2640**

**Table 2.** TVB-2640 was well tolerated

<table>
<thead>
<tr>
<th>Dose</th>
<th>Pre-value</th>
<th>Mean(range)</th>
<th>%Change</th>
<th>Mean(range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>50mg</td>
<td>37 (31-40)</td>
<td>38 (34-42)</td>
<td></td>
</tr>
<tr>
<td>150mg</td>
<td>100 (49-215)</td>
<td>100 (98-101)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>205 (152-317)</td>
<td>230 (235-304)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**CONCLUSIONS**

- Pharmacological inhibition of FASN treats NASH in mice fed a high-fat, high-sugar diet.
- Once-daily dosing of TVB-2640, an oral, highly-selective FASN inhibitor, was supported by its PK profile.
- 50mg of TVB-2640 significantly reduced hepatic DNL by an average of 24%.
- 150mg of TVB-2640 in a subject with a high baseline (pre sugar) rate of lipogenesis potently inhibited hepatic DNL.
- Plasma levels of TVB-2640 strongly correlate with the level of suppression of lipogenesis, enabling dose titration.

**DISCLOSURES**

These studies were sponsored by 3-V Biosciences, Inc.